FrancophonIA/ELRC3.0 huggingface dataset:
English: Administration to patients with: - a family history of sudden death or of congenital prolongation of the QTc interval on electrocardiograms, or with any other clinical condition known to prolong the QTc interval.
Slovenian: Uporaba pri bolnikih z: - družinsko anamnezo nenadne smrti ali prirojenega podaljšanja intervala QTc na elektrokardiogramu ali s katerim koli drugim kliničnim stanjem, za katerega je znano, da podaljša interval QTc, - anamnezo simptomatskih srčnih aritmij ali s klinično pomembno bradikardijo ali s kongestivnim srčnim popuščanjem skupaj z zmanjšanim iztisnim deležem levega prekata.
English: Since efavirenz is principally metabolised by the CYP system, caution should be exercised in administering Atripla to patients with mild hepatic impairment.
Slovenian: Efavirenz predvsem presnavlja sistem CYP, zato je pri uporabi zdravila Atripla pri bolnikih z blago jetrno okvaro potrebna previdnost.
English: A similar reduction in indinavir exposures was observed when indinavir 1,000 mg q8h was given with efavirenz 600 mg q.d.
Slovenian: Podobno zmanjšanje izpostavljenosti indinavirju je opaziti, kadar so bolniki prejemali indinavir 1000 mg vsakih 8 ur z efavirenzom 600 mg dnevno.
English: If you stop taking Atripla Don't stop taking Atripla without talking to your doctor.
Slovenian: Ne prenehajte jemati zdravila Atripla, ne da bi se posvetovali z zdravnikom.
English: The separate pharmaceutical forms of efavirenz, emtricitabine and tenofovir disoproxil were used to determine the pharmacokinetics of efavirenz, emtricitabine and tenofovir disoproxil, administered separately in HIV infected patients.
Slovenian: Za določanje farmakokinetičnih lastnosti efavirenza, emtricitabina in dizoproksiltenofovirata so bile uporabljene ločene farmacevtske oblike efavirenza, emtricitabina in dizoproksiltenofovirata, ki so bile pri bolnikih, okuženih z virusom HIV, uporabljene posebej.
English: Limited clinical experience suggests that emtricitabine and tenofovir disoproxil have an anti-HBV activity when used in antiretroviral combination therapy to control HIV infection.
Slovenian: Omejene klinične izkušnje kažejo, da emtricitabin in dizoproksiltenofovirat v protiretrovirusnem kombiniranem zdravljenju za nadzor okužbe s HIV kažeta delovanje proti HBV.
English: Psychiatric symptoms: Patients with a history of psychiatric disorders appear to be at greater risk of serious psychiatric adverse reactions listed in the efavirenz column of Table 2.
Slovenian: Psihiatrični simptomi: Videti je, da je tveganje za resne psihiatrične neželene reakcije, navedene v stolpcu s podatki o efavirenzu v tabeli 2, večje pri bolnikih s psihiatričnimi motnjami v anamnezi.
English: The adverse reaction profile of efavirenz, emtricitabine and tenofovir disoproxil in patients co-infected with HIV/HBV or HIV/HCV was similar to that observed in patients infected with HIV without co-infection.
Slovenian: Profil neželenih učinkov efavirenza, emtricitabina in dizoproksiltenofovirata pri bolnikih, sočasno okuženih z virusoma HIV in HBV ali virusoma HIV in HCV, je bil podoben profilu, ki so ga opazili pri bolnikih, okuženih z virusom HIV, ki pa niso sočasno okuženi z drugim virusom.
English: If bone abnormalities are suspected then appropriate consultation should be obtained.
Slovenian: Ob sumu na kostne anomalije je treba pridobiti ustrezno strokovno mnenje.
English: The mean (%CV) tenofovir exposure increased from 2,185 ng•h/ml (12%) in patients with normal renal function, to 3,064 ng•h/ml (30%), 6,009 ng•h/ml (42%) and 15,985 ng•h/ml (45%) in patients with mild, moderate and severe renal impairment, respectively.
Slovenian: Srednja vrednost ( % CV) izpostavljenosti tenofovirju se je zvišala od 2,185 µg•h/ml (12 %) pri bolnikih z normalnim delovanjem ledvic na 3,064 µg•h/ml (30 %) pri bolnikih z blago ledvično okvaro, na 6,009 µg•h/ml (42 %) pri bolnikih z zmerno ledvično okvaro ter na 15,985 µg•h/ml (45 %) pri bolnikih s hudo ledvično okvaro.
English: Co-administration of standard doses of efavirenz and voriconazole is contraindicated (see section 4.3).
Slovenian: Sočasna uporaba standardnega odmerka efavirenza in vorikonazola je kontraindicirana (glejte poglavje 4.3)
English: The pharmacokinetics of efavirenz, emtricitabine and tenofovir disoproxil after co-administration of the separate pharmaceutical forms or as Atripla have not been studied in HIV infected patients with renal impairment.
Slovenian: Farmakokinetike efavirenza, emtricitabina in dizoproksiltenofovirata po sočasnem jemanju posameznih farmacevtskih oblik ali v obliki zdravila Atripla niso raziskovali pri bolnikih, okuženih z virusom HIV, ki imajo ledvično okvaro.
English: Gilead Sciences Ltd. Tel: + 44 (0) 8000 113 700
Slovenian: United Kingdom Gilead Sciences Ltd Tel: + 44 (0) 8000 113 700
English: Atripla and sofosbuvir can be co-administered without dose adjustment.
Slovenian: Zdravilo Atripla and sofosbuvir se lahko uporabljata sočasno brez prilagajanja odmerkov.
English: ANTI-INFECTIVES HIV antivirals
Slovenian: Protivirusne učinkovine proti virusu HIV
English: A third subject had pre-existing NNRTI resistance-associated substitutions to efavirenz and the M184V reverse transcriptase resistance-associated substitution to emtricitabine at entry into the Atripla extension phase and experienced a suboptimal virologic response, and developed K65K/R, S68N and K70K/E NRTI resistance-associated substitutions at week 180 (36 weeks on Atripla).
Slovenian: Tretji bolnik je imel že ob vstopu v podaljšano fazo študije zdravila Atripla substitucije za efavirenz, povezane z odpornostjo proti NNRTI, in substitucijo reverzne transkriptaze M184V, povezano z odpornostjo proti emtricitabinu, zato je bil njegov virološki odziv manjši od optimalnega, do 180. tedna (po 36 tednih jemanja zdravila Atripla) pa je razvil substitucije K65K/R, S68N in K70K/E, povezane z odpornostjo proti NRTI.
English: Plasma levels of efavirenz can be reduced by concomitant use of St. John's wort due to induction of drug metabolising enzymes and/or transport proteins by St. John's wort.
Slovenian: Sočasna uporaba šentjanževke lahko zmanjša koncentracije efavirenza v plazmi zaradi indukcije presnovnih encimov in/ali transportnih proteinov.
English: Uncommon hypercholesterolaemia3
Slovenian: Občasni hiperholesterolemija3
English: • decreases in phosphate levels in the blood
Slovenian: • znižanje ravni fosfatov v krvi;
English: Artemether/Lumefantrine/Efavirenz (20/120 mg tablet, 6 doses of 4 tablets each over 3 days/600 mg q.d.)
Slovenian: Antimalariki artemeter/lumefantrin/efavirenz (20/120 mg tableta, 6 odmerkov po 4 tablete v obdobju 3 dni/600 mg dvakrat na dan)
English: When the two strata were analysed separately, response rates in the stratum with prior PI-treatment were numerically lower for patients switched to Atripla [92.4% versus 94.0% for the PVR (sensitivity analysis) for Atripla and SBR patients respectively; a difference (95%CI) of -1.6% (-10.0%, 6.7%).
Slovenian: Pri ločeni analizi dveh skupin je bil delež odziva v skupini s predhodnim zdravljenjem z zaviralci proteaz (ZP) numerično nižji pri bolnikih, ki so prešli na zdravljenje z zdravilom Atripla [vrednost PVR (analiza senzitivnosti) 92,4 % pri bolnikih, ki so prejemali zdravilo Atripla v primerjavi z 94,0 % pri SBR bolnikih; razlika (95 % interval zaupanja) -1,6 % (-10,0 %, 6,7 %)].
English: • increased cholesterol in the blood
Slovenian: • povišano raven holesterola v krvi.
English: Patients must not have experienced failure of a previous HIV therapy.
Slovenian: Pri bolnikih predhodno zdravljenje ni smelo biti neuspešno.
English: Co-administration with terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil, or ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine, and methylergonovine).
Slovenian: Sočasna uporaba s terfenadinom, astemizolom, cisapridom, midazolamom, triazolamom, pimozidom, bepridilom ali alkaloidi rženih rožičkov (na primer ergotaminom, dihidroergotaminom, ergonovinom in metilergonovinom).
English: Carbamazepine:
Slovenian: karbamazepin:
English: Individual tolerability and virological response should be considered when making the dose adjustment (see section 5.2).
Slovenian: Pri prilagoditvi odmerka je treba upoštevati bolnikovo prenašanje in virološki odziv (glejte poglavje 5.2).
English: In the prior-NNRTI stratum, response rates were 98.9% vs 97.4% for Atripla and SBR patients respectively; a difference (95%CI) of 1.4% (-4.0%, 6.9%)].
Slovenian: V skupini s predhodnim NNRTI zdravljenjem je bil delež odziva pri uporabi zdravila Atripla 98,9 %, pri SBR bolnikih pa 97,4 %; razlika (95 % interval zaupanja) 1,4 % (-4,0 %, 6,9 %)].
English: Atripla 600 mg/200 mg/245 mg film-coated tablets
Slovenian: IME ZDRAVILA Atripla 600 mg/200 mg/245 mg filmsko obložene tablete
English: Compounds that are substrates of these enzymes may have decreased plasma concentrations when co-administered with efavirenz.
Slovenian: Plazemske koncentracije spojin, ki so substrati teh encimov, se lahko znižajo pri sočasni uporabi z efavirenzom.
English: • pain in the abdomen (stomach), caused by inflammation of the pancreas
Slovenian: • bolečina v trebuhu (želodcu), ki jo povzroča vnetje trebušne slinavke;
English: Following multiple dose oral administration of emtricitabine to 20 HIV infected patients, steady-state Cmax was 1.8 ± 0.7 µg/ml (mean ± S.D.) (39%CV), steady-state Cmin was 0.09 ± 0.07 µg/ml (80%) and the AUC was 10.0 ± 3.1 µg•h/ml (31%) over a 24 hour dosing interval.
Slovenian: Po peroralnem zaužitju večkratnih odmerkov emtricitabina pri 20 bolnikih, okuženih z virusom HIV, so bile v 24-urnem intervalu odmerjanja vrednosti Cmax v stanju dinamičnega ravnovesja 1,8 ± 0,7 μg/ml (povprečje ± S. D.) (39 % CV), Cmin v stanju dinamičnega ravnovesja 0,09 ± 0,07 μg/ml (80 %) in AUC 10,0 ± 3,1 μg•h/ml (31 %).
English: Atripla should not be coadministered with products containing efavirenz unless needed for dose adjustment e.g. with rifampicin (see section 4.2).
Slovenian: Zdravilo Atripla se ne sme sočasno uporabljati z zdravili, ki vsebujejo efavirenz, razen če je to potrebno za prilagoditev odmerka, npr. z rifampicinom (glejte poglavje 4.2).
English: Elbasvir/grazoprevir: Co-administration of Atripla with elbasvir/grazoprevir is contraindicated because it may lead to loss of virologic response to elbasvir/grazoprevir (see section 4.3 and Table 1).
Slovenian: Elbasvir/grazoprevir: Sočasna uporaba zdravila Atripla z elbasvirjem/grazoprevirjem je kontraindicirana, saj lahko povzroči izgubo virološkega odziva na elbasvir/grazoprevir (glejte poglavje 4.3 in preglednico 1).
English: - Once you start taking Atripla, look out for: - signs of dizziness, difficulty sleeping, drowsiness, difficulty concentrating or abnormal dreaming.
Slovenian: znake omotice, težave pri spanju, zaspanost, težave s koncentracijo ali nenormalne sanje.
English: Anencephaly and unilateral anophthalmia with secondary enlargement of the tongue were observed in one foetus, microophthalmia was observed in another foetus and cleft palate was observed in a third foetus.
Slovenian: Pri enem zarodku so opazili anencefalijo in unilateralno anoftalmijo s sekundarno povečanim jezikom, pri drugem mikrooftalmijo, pri tretjem pa razcepljeno nebo.
English: A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil therapy has been associated with reports of high rates of virologic failure within several tested combinations.
Slovenian: Sočasno zdravljenje z zmanjšanim odmerkom didanozina (250 mg) in dizoproksiltenofoviratom je bilo v več preizkušenih kombinacijah povezano s poročili o visoki stopnji virološke odpovedi.
English: Lopinavir concentrations: similar to lopinavir/ritonavir 400/100 mg twice daily without efavirenz.
Slovenian: Koncentracije lopinavirja: podobne koncentracijam lopinavirja/ritonavirja 400/100 mg dvakrat dnevno brez efavirenza.
English: In patients treated with other medicinal products associated with liver toxicity, monitoring of liver enzymes is also recommended.
Slovenian: Spremljanje jetrnih encimov priporočamo tudi pri bolnikih, ki prejemajo druga zdravila, povezana s toksičnostjo za jetra.
English: Atripla must not be administered concurrently with terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil, or ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine, and methylergonovine), since inhibition of their metabolism may lead to serious, life-threatening events (see section 4.3).
Slovenian: Zdravilo Atripla se ne sme uporabljati sočasno s terfenadinom, astemizolom, cisapridom, midazolamom, triazolamom, pimozidom, bepridilom ali alkaloidi rženih rožičkov (npr. ergotaminom, dihidroergotaminom, ergonovinom in metilergonovinom), ker bi zaviranje njihove presnove lahko povzročilo hude, življenjsko nevarne neželene učinke (glejte poglavje 4.3).
English: Itraconazole:
Slovenian: itrakonazol:
English: Since Atripla is a fixed-dose combination product, the dose of efavirenz cannot be altered; therefore, voriconazole and Atripla must not be co-administered (see section 4.3 and Table 1).
Slovenian: Ker je zdravilo Atripla zdravilo s fiksno kombinacijo odmerkov, se odmerek efavirenza ne more spremeniti, zato se vorikonazol in zdravilo Atripla ne smeta uporabljati sočasno (glejte poglavje 4.3 in tabelo 1).
English: Blood and lymphatic system disorders: Common neutropenia
Slovenian: Bolezni krvi in limfatičnega sistema Pogosti nevtropenija
English: -0.5% (-3.2% to 2.2%)
Slovenian: -0,5 % (-3,2 % do 2,2 %)
English: Due to similarities with emtricitabine, Atripla should not be administered concomitantly with other cytidine analogues, such as lamivudine.
Slovenian: Zaradi podobnosti z emtricitabinom se zdravilo Atripla ne sme uporabljati sočasno z drugimi analogi citidina, kot je lamivudin.
English: AUC: ↔* (↓ 9% to ↑ 10%) Cmax: ↑ 17%* (↑ 8 to ↑ 27) Cmin: ↓ 42%* (↓ 31 to ↓ 51)
Slovenian: AUC: ↔* (↓ 9 % do ↑ 10 %) Cmax: ↑ 17 %* (↑ 8 do ↑ 27) Cmin: ↓ 42 %* (↓ 31 do ↓ 51)
English: No dose adjustment of rifampicin is recommended when given with Atripla.
Slovenian: Prilagoditve odmerka rifampicina pri sočasni uporabi z efavirenzom ne priporočamo.
English: After 96 weeks of Atripla treatment, HIV-1 RNA plasma concentrations remained < 50 copies/ml in 82% of patients and < 400 copies/ml in 85% of patients (intention to treat analysis (ITT), missing=failure).
Slovenian: v plazmi pri 82 % bolnikov < 50 kopij/ml in pri 85 % bolnikov < 400 kopij/ml (analiza populacije, ki so jo nameravali zdraviti (analiza ITT), nepopoln = neuspešen).
English: Hydroxybupropion:
Slovenian: hidroksibupropion:
English: Atripla can reduce the amount of statins in your blood.
Slovenian: Zdravilo Atripla lahko zniža količino statinov v krvi.
English: Co-administration with other medicinal products
Slovenian: Sočasna uporaba z drugimi zdravili
English: Atripla is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate.
Slovenian: Zdravilo Atripla je fiksna kombinacija odmerkov efavirenza, emtricitabina in dizoproksiltenofovirijevega fumarata.
English: Proguanil:
Slovenian: progvanil:
English: Refer to the Summary of Product Characteristics for elbasvir/grazoprevir for more information.
Slovenian: Za več podatkov glejte povzetek glavnih značilnosti zdravila zaelbasvir/grazoprevir.
English: - Medicines used to prevent organ transplant rejection (also called immunosuppressants),
Slovenian: - Zdravila za preprečevanje zavrnitve presajenih organov (imenovana tudi imunosupresivi), kakršna so ciklosporin, sirolimus ali takrolimus.
English: • pain, stomach pain
Slovenian: • bolečina, bolečina v želodcu;
English: AUC: ↑ 32% (↑ 25 to ↑ 38) Cmax: ↔
Slovenian: AUC:↑ 32 % (↑ 25 do ↑ 38) Cmax: ↔
English: Barrier contraception should always be used in combination with other methods of contraception (for example, oral or other hormonal contraceptives, see section 4.5) while on therapy with Atripla.
Slovenian: V času zdravljenja z zdravilom Atripla je treba vedno uporabljati mehansko kontracepcijo v kombinaciji z drugimi kontracepcijskimi metodami (na primer s peroralnimi ali drugimi hormonskimi kontraceptivi, glejte poglavje 4.5).
English: Where discontinuation of therapy with one of the components of Atripla is indicated or where dose modification is necessary, separate preparations of efavirenz, emtricitabine and tenofovir disoproxil are available.
Slovenian: Kadar je indicirana prekinitev zdravljenja z eno izmed učinkovin zdravila Atripla ali če je prilagoditev odmerka nujna, so na voljo efavirenz, emtricitabin in dizoproksiltenofovirat v ločenih zdravilih.
English: Stayed on original treatment regimen (N=97) n/N (%)
Slovenian: Bolniki, ki so ostali na prvotnem zdravljenju (N = 97)
English: Limited data suggest that females may have higher exposure to efavirenz but they do not appear to be less tolerant of efavirenz.
Slovenian: Pomanjkljivi podatki kažejo višjo izpostavljenost efavirenzu, a ne kaže, da bi le-ti zdravilo prenašali slabše.
English: Concomitant administration of Atripla and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/ voxilaprevir is expected to decrease plasma concentrations of velpatasvir and voxilaprevir.
Slovenian: Pričakuje se, da sočasna uporaba zdravila Atripla in sofosbuvirja/velpatasvirja ali sofosbuvirja/velpatasvirja/ voksilaprevirja zmanjšala koncentracije velpatasvirja in voksilaprevirja v plazmi.
English: Plasma trough concentrations of boceprevir were decreased when administered with efavirenz, a component of Atripla.
Slovenian: Najmanjše koncentracije boceprevira v plazmi so se znižale, ko je bil boceprevir injiciran skupaj z efavirenzom, učinkovino zdravila Atripla.
English: • rashes (including red spots or blotches sometimes with blistering and swelling of the skin),
Slovenian: • izpuščaji (vključno z rdečimi pikami ali madeži, ki jih včasih spremljajo mehurji in otekanje kože), ki so lahko posledica alergijske reakcije;
English: Sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir: Co-administration of Atripla and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir is not recommended (see section 4.4 and Table 1)
Slovenian: Sofosbuvir/velpatasvir in sofosbuvir/velpatasvir/voksilaprevir: Sočasne uporabe zdravila Atripla in sofosbuvirja/velpatasvirja ali sofosbuvirja/velpatasvirja/voksilaprevirja ne priporočamo (glejte poglavje 4.4 in tabelo 1).
English: K103N was the most frequently observed RT substitution in viral isolates from patients who experienced rebound in viral load during clinical studies of efavirenz.
Slovenian: Najpogostejša substitucija RT pri izolatih, pridobljenih pri bolnikih, pri katerih je med kliničnimi študijami efavirenza prišlo do povečanja koncentracije virusa, je bila K103N.
English: Buprenorphine/naloxone/Emtricitabine Interaction not studied.
Slovenian: buprenorfin/nalokson/emtricitabin Interakcij niso preučevali.
English: No human data on the effect of Atripla are available.
Slovenian: Ni razpoložljivih podatkov o vplivu zdravila Atripla na ljudi.
English: Patients had never experienced virological failure on a previous antiretroviral therapy, had no known HIV-1 mutations that confer resistance to any of the three components within Atripla, and had been virologically suppressed for at least three months at baseline.
Slovenian: Bolniki niso imeli nobenih znanih mutacij HIV-1, odgovornih za odpornost na katero od treh učinkovin zdravila Atripla in so imeli na začetku vsaj tri mesece virusno supresijo.
English: Some examples include, but are not limited to, aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2 (see section 4.4).
Slovenian: Med takimi zdravili so tudi aminoglikozidi, amfotericin B, foskarnet, ganciklovir, pentamidin, vankomicin, cidofovir ali interlevkin-2 (glejte poglavje 4.4).
English: 3 See section 4.8 Description of selected adverse reactions for more details.
Slovenian: 3 Za več podrobnosti glejte poglavje 4.8.
English: 0.5% (-7.0% to 9.3%)
Slovenian: 0,5 % (-7,0 % do 9,3 %)
English: Due to the similarity between lamivudine and emtricitabine, a component of Atripla, Atripla should not be administered concomitantly with lamivudine (see section 4.4).
Slovenian: Zaradi podobnosti lamivudina z emtricitabinom, učinkovino zdravila Atripla, se zdravilo Atripla ne sme uporabljati sočasno z lamivudinom (glejte poglavje 4.4).
English: Atripla may interact with other medicines, including herbal preparations such as Ginkgo biloba extracts.
Slovenian: Zdravilo Atripla lahko medsebojno deluje z drugimi zdravili, vključno s pripravki rastlinskega izvora, kot so izvlečki ginka (Ginkgo biloba), kar lahko vpliva na količino zdravila Atripla ali drugih zdravil v krvi.
English: Non-sustained convulsions were observed in some monkeys receiving efavirenz for ≥ 1 year, at doses yielding plasma AUC values 4- to 13-fold greater than those in humans given the recommended dose.
Slovenian: Pri nekaterih opicah, ki so prejemale efavirenz ≥ 1 leto, so opazili prehodne konvulzije pri uporabi odmerkov, s katerimi so dosegli od 4- do 13-krat večje vrednosti AUC kot pri ljudeh, ki so prejemali priporočene odmerke.
English: AUC: ↓ 43% (↓ 7 to ↓ 65) Cmax: ↔
Slovenian: AUC: ↓ 43 % (↓ 7 do ↓ 65) Cmax: ↔
English: Co-administration of tenofovir disoproxil and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosine-related adverse reactions.
Slovenian: Sočasna uporaba dizoproksiltenofovirata in didanozina je povzročila 40-60 % povečanje sistemske izpostavljenosti didanozinu,
English: There were no clinically significant pharmacokinetic interactions when emtricitabine was administered with stavudine, zidovudine or famciclovir.
Slovenian: Klinično pomembnih farmakokinetičnih interakcij pri sočasni uporabi emtricitabina in stavudina, zidovudina ali famciklovirja ni bilo.
English: Simeprevir/Emtricitabine
Slovenian: simeprevir/emtricitabin
English: The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index, among others, may be some of the many risk factors for developing this disease.
Slovenian: Nekateri izmed mnogih dejavnikov tveganja za nastanek te bolezni so lahko med drugim trajanje kombiniranega protiretrovirusnega zdravljenja, uporaba kortikosteroidov, uživanje alkohola, huda imunska supresija in višji indeks telesne mase.
English: If the patient vomits more than 1 hour after taking Atripla he/she does not need to take another dose.
Slovenian: Če bolnik tableto izbruha več kot 1 uro po zaužitju zdravila Atripla, mu ni treba vzeti še enega odmerka.
English: Rarely, pancreatitis and lactic acidosis, sometimes fatal, have been reported.
Slovenian: Poročali so o redkih primerih pankreatitisa in laktacidoze, ki je bila včasih smrtna.
English: Eye disorders: Uncommon vision blurred
Slovenian: Očesne bolezni: Občasni zamegljen vid
English: Co-administration of Atripla and didanosine is not recommended since exposure to didanosine is significantly increased following co-administration with tenofovir disoproxil that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Slovenian: Sočasne uporabe zdravila Atripla in didanozina ne priporočamo, saj se izpostavljenost didanozinu po sočasni uporabi z dizoproksiltenofoviratom pomembno poveča, kar lahko poveča tveganje za pojav neželenih učinkov, povezanih z didanozinom (glejte poglavje 4.5).
English: It is anticipated that tenofovir exposure (AUC) will be approximately 30% lower following administration of Atripla on an empty stomach as compared to the individual component tenofovir disoproxil when taken with food (see section 5.2).
Slovenian: Po zaužitju zdravila Atripla na prazen želodec je pričakovana izpostavljenost (AUC) tenofovirju približno za 30 % manjša kot pri zaužitju samega dizoproksiltenofovirata s hrano (glejte poglavje 5.2).